Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Paroxysmal Hemoglobinuria, Nocturnal: full-pipeline trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
Paroxysmal Hemoglobinuria, Nocturnal: 2 US clinical trials tracked, none currently recruiting.
Paroxysmal Hemoglobinuria, Nocturnal is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Alexion Pharmaceuticals, running 1 of these trials.
Enrollment posture brief
Registry condition paroxysmal-hemoglobinuria-nocturnal
OPEN 0 | RECR 0% | LATE 1 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Paroxysmal Hemoglobinuria, Nocturnal has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Paroxysmal Hemoglobinuria, Nocturnal on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Paroxysmal Hemoglobinuria, Nocturnal is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
Alexion Pharmaceuticals
NCT00122317
Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00004464
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Paroxysmal Hemoglobinuria, Nocturnal records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Paroxysmal Hemoglobinuria, Nocturnal trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Paroxysmal Hemoglobinuria, Nocturnal page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Paroxysmal Hemoglobinuria, Nocturnal trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Alexion Pharmaceuticals sponsors the most Paroxysmal Hemoglobinuria, Nocturnal trials on record, review their full trial history before evaluating a specific study. See Alexion Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Paroxysmal Hemoglobinuria, Nocturnal condition card totals 2 registered trials; most-linked intervention eculizumab; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.